In vitro evaluation of novel reverse transcriptase inhibitors TAF (tenofovir alafenamide) and OBP-601 (2,3-didehydro-3-deoxy-4-ethynylthymidine) against multi-drug resistant primary isolates of HIV-2-Reference-Cited by-同舟云学术

In vitro evaluation of novel reverse transcriptase inhibitors TAF (tenofovir alafenamide) and OBP-601 (2,3-didehydro-3-deoxy-4-ethynylthymidine) against multi-drug resistant primary isolates of HIV-2

Published:2019-01 Issue: Volume:161 Page:85-89
ISSN:0166-3542
Container-title:Antiviral Research
language:en
Short-container-title:Antiviral Research

Author:

Bártolo Inês,Borrego Pedro,Gomes Perpétua^ORCID,Gonçalves Fátima,Caixas Umbelina,Pinto Inês V.,Taveira Nuno

Funder

Fundação para a Ciência e a Tecnologia

LIFE

European and Developing Countries Clinical Trials Partnership

Publisher

Elsevier BV

Subject

Virology,Pharmacology

Reference43 articles.

1. Amino acid residues in HIV-2 reverse transcriptase that restrict the development of nucleoside analogue resistance through the excision pathway;Alvarez;J. Biol. Chem.,2018

2. Baseline susceptibility of primary HIV-2 to entry inhibitors;Borrego;Antivir. Ther.,2012

3. Pol gene sequence variation in Swedish HIV-2 patients failing antiretroviral therapy;Brandin;AIDS Res. Hum. Retrovir.,2003

4. In vitro virology profile of tenofovir alafenamide, a novel oral prodrug of tenofovir with improved antiviral activity compared to that of tenofovir disoproxil fumarate;Callebaut;Antimicrob. Agents Chemother.,2015

5. Population mobility and the changing epidemics of HIV-2 in Portugal;Carvalho;HIV Med.,2012

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Antiretroviral Treatment of HIV-2 Infection: Available Drugs, Resistance Pathways, and Promising New Compounds;International Journal of Molecular Sciences;2023-03-21

2. High Instantaneous Inhibitory Potential of Bictegravir and the New Spiro-β-Lactam BSS-730A for HIV-2 Isolates from RAL-Naïve and RAL-Failing Patients;International Journal of Molecular Sciences;2022-11-18

3. Comparison of the Antiviral Activity of Bictegravir against HIV-1 and HIV-2 Isolates and Integrase Inhibitor-Resistant HIV-2 Mutants;Antimicrobial Agents and Chemotherapy;2019-05